Video

Our team behind the scenes at SXSW | Next steps: From molecule design to medicine

Following target identification and endotyping, we have the ability to design molecule compounds and progress these into clinical trials. In this final video, our team walks through our approach in this video to conclude the series from our SXSW keynote session.

Our team was able to identify lists of possible gene targets involved in disease by applying AI models on diverse sets of data such as scientific literature, patents, chemical databases, and patient data such as electronic health records or multi-omics datasets.

Following the generation of the list of targets, molecular design can start. Here we try to tackle an important aspect of making the drug brain penetrant. This is an important step where our team of scientists and machine learning researchers identify, design and test the best molecules.

The collaboration between our scientists and machine learning researchers gives us the ability to rethink and improve the process of drug discovery and development. Patients are at the heart of everything we do and this is reflected in our approach.

More Posts

You Might Also Like

Blog
Intern at BenevolentAI part I: meet our 2020 intern cohort
What impactful work did our interns get up to across Engineering, Data Science, ML and business operations this summer? Get to know them and their work in our tech internships blog.
Nov 26, 2020
News
FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI
BenevolentAI scientists first identified baricitinib as a potential treatment for COVID-19 in early February 2020 using Benevolent's AI tools and biomedical knowledge graph.
Nov 20, 2020
News
NeurIPS 2020: Meet the BenevolentAI team
BenevolentAI is happy to announce it is sponsoring NeurIPS 2020. Join us to hear about data diversity and ML applied drug discovery, and to learn about careers in the field.
Nov 17, 2020
Blog
Careers with Impact: 5 learnings from machine learning applied drug discovery
Last week, we brought together four of our exceptional colleagues for a panel discussion on careers in machine learning applied drug discovery. Here are some of our main takeaways:
Nov 17, 2020
Blog
Data published in Science Advances shows baricitinib reduces COVID-19 morbidity and mortality
Research published in Science Advances supports BenevolentAI’s AI-generated hypothesis from late January for baricitinib as a treatment for COVID-19.
Nov 13, 2020
News
Sir Nigel Shadbolt joins BenevolentAI as a non-executive director
BenevolentAI strengthens its Board with the appointment of AI pioneer Sir Nigel Shadbolt as Non-Executive Director.
Nov 3, 2020